da Silva Ticyana Moralez, Munhoz Renato Puppi, Alvarez Cristiano, Naliwaiko Katya, Kiss Agata, Andreatini Roberto, Ferraz Anete Curte
Laboratório de Neurofisiologia, Departamento de Fisiologia, Universidade Federal do Paraná, C.P. 19.031, 81.531-990 Curitiba, PR, Brazil.
J Affect Disord. 2008 Dec;111(2-3):351-9. doi: 10.1016/j.jad.2008.03.008. Epub 2008 May 15.
Effect of fish oil supplementation in parkinsonian patients with depression measured by Montgomery-Asberg Rating Scale (MADRS), the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BECK).
Double-blind, placebo-controlled study analyzed depression in 31 patients with Parkinson's Disease and Major Depression (DSM-IV). The patients were double-blind separated in 2 groups that received fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months; each group was separated in 2 new groups: one taking antidepressant medication and another one not taking it.
29 patients completed the 12-week trial, 58% were female and the mean age was 64.4 years old. Patients supplemented with fish oil showed a significant decrease in MADRS and CGI-Depression scores, and there was no difference among groups in BDI. 14 patients (42%) met criteria for > or = 50% reduction in MADRS score, 7 patients (22%) met criteria for remission (final MADRS total score < or = 12), and 2 patients (6%) discontinued supplementation of fish oil. HPLC analysis of fatty-acid profile showed increase of omega-3 fatty acid in the erythrocyte membrane of patients taking fish oil.
These results reveal that PD patients taking fish oil, with or without antidepressants, presented improvement in depressive symptoms and indicate that the intake of omega-3 can be used with an antidepressant effect or as adjuvant therapy with some other medication. This is a first pilot study with parkinsonian patients and omega-3 supplementation and requires replication in a larger sample.
采用蒙哥马利-艾斯伯格抑郁量表（MADRS）、临床总体印象量表（CGI）和贝克抑郁量表（BECK）来衡量补充鱼油对帕金森病伴抑郁症患者的影响。
一项双盲、安慰剂对照研究分析了31例帕金森病伴重度抑郁症（DSM-IV）患者的抑郁情况。患者被双盲分为两组，一组服用鱼油（含ω-3脂肪酸）胶囊，另一组服用矿物油胶囊，为期3个月；每组又分为两个新组：一组服用抗抑郁药物，另一组不服用。
29例患者完成了为期12周的试验，其中58%为女性，平均年龄为64.4岁。补充鱼油的患者MADRS和CGI-抑郁评分显著降低，BDI在各组间无差异。14例患者（42%）符合MADRS评分降低≥50%的标准，7例患者（22%）符合缓解标准（最终MADRS总分≤12），2例患者（6%）停止补充鱼油。脂肪酸谱的高效液相色谱分析显示，服用鱼油患者的红细胞膜中ω-3脂肪酸增加。
这些结果表明，服用鱼油的帕金森病患者，无论是否服用抗抑郁药，抑郁症状均有改善，提示摄入ω-3可产生抗抑郁作用或作为其他药物的辅助治疗。这是一项关于帕金森病患者和ω-3补充剂的初步试验研究，需要在更大样本中重复验证。
